Drug Interactions
Enzalutamide Interactions
Acetylsalicylic acid
No clinically significant drug interactions identified.
Alprazolam
Caution - decreased level of alprazolam due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Amitriptyline
No clinically significant drug interactions identified.
Amlodipine
Caution - decreased level of amlodipine due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Amoxicillin
No clinically significant drug interactions identified.
Amoxicillin/clavulanate
No clinically significant drug interactions identified.
Apixaban
Avoid combination - decreased level of apixaban due to 3A4 induction. Choose an alternative agent.
Atenolol
No clinically significant drug interactions identified.
Atorvastatin
Caution - decreased level of atorvastatin due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Azithromycin
No clinically significant drug interactions identified.
Bisoprolol
Caution - decreased level of bisoprolol due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Canagliflozin
No clinically significant drug interactions identified.
Candesartan
No clinically significant drug interactions identified.
Carbamazepine
Avoid combination - decreased level of enzalutamide due to 3A4 induction. Decreased level of carbamazepine due to 3A4 induction. Choose an alternative agent.
Carvedilol
Caution - decreased level of carvedilol due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Chlorthalidone
No clinically significant drug interactions identified.
Ciprofloxacin
No clinically significant drug interactions identified.
Citalopram
Caution - decreased level of citalopram due to 2C19/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Clarithromycin
Avoid combination - decreased level of clarithromycin due to 3A4 induction. Choose an alternative agent.
Clomipramine
No clinically significant drug interactions identified.
Clonazepam
Caution - decreased level of clonazepam due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Clopidogrel
Avoid combination - increased level of enzalutamide due to 2C8 inhibition. Choose an alternative agent.
Codeine
Caution - decreased level of codeine due to 3A4 induction. This results in an increased level of inactive metabolite "norcodeine", as opposed to its active metabolite of morphine through 2D6 metabolism. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Dabigatran
Caution - increased level of dabigatran due to Pgp inhibition. Monitor for signs of bleeding - a dose reduction may be required. Consider choosing an alternative agent.
Dapagliflozin
No clinically significant drug interactions identified.
Degarelix
No clinically significant drug interactions identified.
Desipramine
No clinically significant drug interactions identified.
Dexamethasone
Caution - decreased level of dexamethasone due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required.
Dexlansoprazole
Caution - decreased level of dexlansoprazole due to 2C19 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Diltiazem
Avoid combination - decreased level of diltiazem due to 3A4 induction. Choose an alternative agent.
Doxycycline
No clinically significant drug interactions identified.
Duloxetine
No clinically significant drug interactions identified.
Dutasteride
No clinically significant drug interactions identified.
Edoxaban
Caution - increased level of edoxaban due to Pgp inhibition. Monitor for signs of bleeding - a dose reduction may be required. Consider choosing an alternative agent.
Empagliflozin
No clinically significant drug interactions identified.
Escitalopram
Caution - decreased level of escitalopram due to 2C19/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Esomeprazole
No clinically significant drug interactions identified.
Famotidine
No clinically significant drug interactions identified.
Finasteride
No clinically significant drug interactions identified.
Fluconazole
No clinically significant drug interactions identified.
Fluoxetine
No clinically significant drug interactions identified.
Furosemide
No clinically significant drug interactions identified.
Gabapentin
No clinically significant drug interactions identified.
Gliclazide
Caution - decreased level of gliclazide due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Glyburide
Caution - decreased level of glyburide due to 2C9 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Goserelin
No clinically significant drug interactions identified.
Hydrochlorothiazide
No clinically significant drug interactions identified.
Hydromorphone
No clinically significant drug interactions identified.
Ibuprofen
No clinically significant drug interactions identified.
Irbesartan
No clinically significant drug interactions identified.
Lansoprazole
Caution - decreased level of lansoprazole due to 2C19/2C9/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Leuprolide
No clinically significant drug interactions identified.
Levofloxacin
No clinically significant drug interactions identified.
Levothyroxine
No clinically significant drug interactions identified.
Lorazepam
No clinically significant drug interactions identified.
Metformin
No clinically significant drug interactions identified.
Methadone
Avoid combination - decreased level of methadone due to 3A4/2C19/2C9 induction. Choose an alternative agent.
Metoclopramide
No clinically significant drug interactions identified.
Metoprolol
No clinically significant drug interactions identified.
Mirabegron
Caution - decreased level of mirabegron due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Mirtazapine
Caution - decreased level of mirtazepine due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Moxifloxacin
No clinically significant drug interactions identified.
Naproxen
No clinically significant drug interactions identified.
Nifedipine XL
Avoid combination - decreased level of nifedipine due to 3A4 induction. Choose an alternative agent.
Nirapirib
No clinically significant drug interactions identified.
Nortriptyline
No clinically significant drug interactions identified.
Olanzapine
No clinically significant drug interactions identified.
Olaparib
Avoid combination - decreased level of olaparib due to 3A4 induction. Choose an alternative agent.
Omeprazole
Caution - decreased level of omeprazole due to 2C19/2C9/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Ondansetron
Caution - decreased level of ondansetron due to 2C9/3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Oxybutynin
No clinically significant drug interactions identified.
Oxycodone
Caution - decreased level of oxycodone due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Pantoprazole
No clinically significant drug interactions identified.
Paroxetine
No clinically significant drug interactions identified.
Perinodopril
No clinically significant drug interactions identified.
Phenytoin
Avoid combination - decreased level of enzalutamide due to 3A4 induction. Decreased level of phenytoin due to 2C19/2C9/3A4 induction. Choose an alternative agent.
Prednisone
Caution - decreased level of prednisone due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required.
Pregabalin
No clinically significant drug interactions identified.
Prochlorperazine
No clinically significant drug interactions identified.
Quetiapine
Avoid combination - decreased level of quetiapine due to 3A4 induction. Choose an alternative agent.
Rabeprazole
No clinically significant drug interactions identified.
Ramipril
No clinically significant drug interactions identified.
Ranitidine
No clinically significant drug interactions identified.
Risperidone
Avoid combination - decreased level of risperidone due to 3A4 induction. Do not use for treatment of schizophrenia or bipolar disorder. For agitation, higher doses than anticipated may be needed for efficacy. Choose an alternative agent.
Rivaroxaban
Avoid combination - decreased level of rivaroxaban due to 3A4 induction. Choose an alternative agent.
Rosuvastatin
No clinically significant drug interactions identified.
Semaglutide
No clinically significant drug interactions identified.
Sertraline
Caution - decreased level of sertraline due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
Sildenafil
Avoid combination (in pulmonary hypertension) - decreased level of sildenafil due to 3A4 induction. If use for erectile dysfunction, monitor for efficacy - higher doses than anticipated may be required.
Silodosin
No clinically significant drug interactions identified.
Simvastatin
Avoid combination - decreased level of simvastatin due to 3A4 induction. Choose an alternative agent.
Sitagliptin
No clinically significant drug interactions identified.
Sulfamethoxazole-trimethoprim
Caution - increased level of enzalutamide due to 2C8 inhibition. Monitor for signs of enzalutamide toxicity - a dose reduction may be required. Consider choosing an alternative agent.
Tadalafil
Avoid combination (in pulmonary hypertension) - decreased level of tadalafil due to 3A4 induction. If use for erectile dysfunction, monitor for efficacy - higher doses than anticipated may be required.
Talazoparib
No clinically significant drug interactions identified.
Tamsulosin
No clinically significant drug interactions identified.
Terazocin
No clinically significant drug interactions identified.
Ticagrelor
Avoid combination - decreased level of ticgrelor due to 3A4 induction. Choose an alternative agent.
Tolterodine
No clinically significant drug interactions identified.
Tramadol
Caution - decreased level of tramadol due to 3A4 induction. Monitor for efficacy - higher doses than anticipated may be required. Consider choosing an alternative agent.
